Haematology – Publications

HAEMATOLOGY DEPARTMENT – PUBLICATION (2015-2018)

 The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.

Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V.

Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002/hon.2551. Epub 2018 Sep 7.

PMID: 30129144

 

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M.

Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002/hon.2521. Epub 2018 Jun 8.

PMID: 29882363

 

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8.

PMID: 29943159

 

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Erratum in: Ann Hematol. 2018 Jun 26;:.

PMID: 29756171

 

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.

Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.

Leuk Res. 2018 Aug;71:55-59. doi: 10.1016/j.leukres.2018.07.004. Epub 2018 Jul 7. No abstract available.

PMID: 30007218

 

Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.

Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P.

Anticancer Res. 2018 Jul;38(7):4187-4191. doi: 10.21873/anticanres.12712.

PMID: 29970548

 

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

PMID: 29856685

 

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient.

Lionaki S, Tsakonas E, Androulaki A, Liapis G, Panayiotidis P, Zavos G, Boletis JN.

Case Rep Nephrol. 2018 May 13;2018:7425785. doi: 10.1155/2018/7425785. eCollection 2018.

PMID: 29862100

 

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID: 29735299

 

The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.

Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.

Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16.

PMID: 29659040

 

Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.

Boutsikas G, Terpos E, Papatheodorou A, Tsirkinidis P, Tsirigotis P, Meletiou A, Lalou E, Telonis V, Zannou A, Kanellopoulos A, Galani Z, Stefanou A, Tsaftaridis P, Viniou NA, Panayiotidis P, Kyrtsonis MC, Meletis J, Vassilakopoulos TP, Angelopoulou MK.

Eur J Haematol. 2018 Feb;100(2):131-139. doi: 10.1111/ejh.12990. Epub 2017 Dec 4.

PMID: 29105864

 

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P.

Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002/hon.2383. Epub 2017 Feb 20.

PMID: 28219112

 

Evaluation of the performance of tuberculin skin test and Quantiferon-TB gold in tube test in patients with hematologic malignancies.

Diamantopoulos PT, Tsilimidos GD, Zervakis K, Polonyfi K, Sofotasiou M, Kyrtsonis MC, Aessopos A, Kyriakakis G, Viniou NA.

Infect Dis (Lond). 2017 Jul;49(7):545-548. doi: 10.1080/23744235.2017.1280619. Epub 2017 Jan 25. No abstract available. Erratum in: Infect Dis (Lond). 2017 Nov – Dec;49(11-12):878.

PMID: 28121214

 

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.

Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group.

Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26.

PMID: 28675766

 

The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials.

Angelopoulou MK, Mosa E, Pangalis GA, Rondogianni P, Chatziioannou S, Prassopoulos V, Moschogianni M, Tsirkinidis P, Asimakopoulos JV, Konstantinou I, Tsourouflis G, Sachanas S, Yiakoumis X, Boutsikas G, Arapaki M, Gainaru G, Kyrtsonis MC, Siakantaris MP, Datseris I, Panayiotidis P, Konstantopoulos K, Vassilakopoulos TP.

Anticancer Res. 2017 Oct;37(10):5727-5736.

PMID: 28982893

 

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID: 28976790

 

High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.

Dimou M, Roumelioti M, Dimitrakopoulou A, Bitsani C, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P.

Leuk Lymphoma. 2018 May;59(5):1264-1267. doi: 10.1080/10428194.2017.1375108. Epub 2017 Sep 13. No abstract available.

PMID: 28901815

 

Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.

Tsirkinidis P, Terpos E, Boutsikas G, Papatheodorou A, Anargyrou K, Lalou E, Dimitrakopoulou A, Kalpadakis C, Konstantopoulos K, Siakantaris M, Panayiotidis P, Pangalis G, Kyrtsonis MC, Vassilakopoulos T, Angelopoulou MK.

J Bone Miner Metab. 2018 Jul;36(4):399-409. doi: 10.1007/s00774-017-0853-4. Epub 2017 Jun 28.

PMID: 28660376

 

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

PMID: 29523783

 

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P.

Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002/hon.2383. Epub 2017 Feb 20.

PMID: 28219112

 

Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).

Kalpadakis C, Pangalis GA, Vassilakopoulos TP, Roumelioti M, Sachanas S, Korkolopoulou P, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Pontikoglou C, Rondoyianni D, Papadaki HA, Panayiotidis P, Angelopoulou MK.

Hematol Oncol. 2017 Dec;35(4):542-547. doi: 10.1002/hon.2361. Epub 2016 Oct 13.

PMID: 27734522

 

Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.

P Vassilakopoulos T, Levidou G, Milionis V, Hartmann S, Lakiotaki E, Sepsa A, Thymara I, Ntailiani P, Spanou K, K Angelopoulou M, P Siakantaris M, Moschogiannis M, A Pangalis G, Panayiotidis P, Konstantopoulos K, Patsouris E, Hansmann ML, Korkolopoulou P.

Leuk Lymphoma. 2017 Sep;58(9):1-13. doi: 10.1080/10428194.2017.1289520. Epub 2017 Jun 2.

PMID: 28571489

 

Cadherin-11 (CDH11) expression in the peripheral blood of patients with active Multiple Myeloma.

Christopoulos PF, Sfikakis PP, Nikolaou E, Terpos E, Koutsilieris M, Kyrtsonis MC.

Br J Haematol. 2017 Jun;177(5):813-816. doi: 10.1111/bjh.14105. Epub 2016 Apr 26. No abstract available.

PMID: 27118219

 

Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID: 27956157

 

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.

Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21.

PMID: 27872060

 

New evidence of gene inactivation by aberrant DNA-Methylation in T-cell leukemia, with treatment implications.

Kyrtsonis MC, Maltezas D.

Leuk Res. 2016 Nov;50:29-30. doi: 10.1016/j.leukres.2016.09.010. Epub 2016 Sep 6. No abstract available.

PMID: 27649494

 

Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.

Angelopoulou MK, Asimakopoulos JV, Galani Z, Levidou G, Roumelioti M, Vassilakopoulos TP, Korkolopoulou P, Panayiotidis P.

Blood Cancer J. 2016 Aug 26;6(8):e461. doi: 10.1038/bcj.2016.66. No abstract available.

PMID: 27564459

 

Response to ‘PET after response to R-CHOP in primary mediastinal large B-cell lymphoma’.

Vassilakopoulos TP, Papageorgiou S, Pangalis GA, Chatziioannou S, Angelopoulou MK,Panayiotidis P, Konstantopoulos K, Rondogianni P.

Leukemia. 2016 Aug;30(8):1800-1. doi: 10.1038/leu.2016.109. Epub 2016 Jun 3. No abstract available.

PMID: 27256701

 

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.

Flinn IW, Panayiotidis P, Afanasyev B, Janssens A, Grosicki S, Homenda W, Smolej L, Kuliczkowski K, Doubek M, Domnikova N, West SL, Chang CN, Barker AM, Gupta IV, Wright OJ, Offner F.

Am J Hematol. 2016 Sep;91(9):900-6. doi: 10.1002/ajh.24430. Epub 2016 Jul 3.

PMID: 27222473

 

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia.

Gavriatopoulou M, Kastritis E, Kyrtsonis MC, Vassilakopoulos TP, Roussou M, Fotiou D, Migkou M, Mpakiri M, Tasidou A, Terpos E, Dimopoulos MA.

Leuk Lymphoma. 2017 Jun;58(6):1506-1508. doi: 10.1080/10428194.2016.1233541. Epub 2016 Oct 10. No abstract available.

PMID: 27724158

 

Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia.

Diamantopoulos PT, Sofotasiou M, Georgoussi Z, Giannakopoulou N, Papadopoulou V, Galanopoulos A, Kontandreopoulou E, Zervakis P, Pallaki P, Kalala F, Kyrtsonis MC, Dimitrakopoulou A, Vassilakopoulos T, Angelopoulou M, Spanakis N, Viniou NA.

Cancer Med. 2016 Sep;5(9):2240-8. doi: 10.1002/cam4.804. Epub 2016 Jul 1.

PMID: 27367207

 

Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.

Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, Petevi K, Pangalis GA, Moschogiannis M, Dimou M, Boutsikas G, Kanellopoulos A, Gainaru G, Plata E, Flevari P, Koutsi K, Papageorgiou L, Telonis V, Tsaftaridis P, Sachanas S, Yiakoumis X, Tsirkinidis P, Viniou NA, Siakantaris MP, Variami E, Kyrtsonis MC, Meletis J, Panayiotidis P, Konstantopoulos K.

Oncologist. 2016 Mar;21(3):343-53. doi: 10.1634/theoncologist.2015-0251. Epub 2016 Feb 26.

PMID:26921291

 

Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.

Lakiotaki E, Levidou G, Angelopoulou MK, Adamopoulos C, Pangalis G, Rassidakis G, Vassilakopoulos T, Gainaru G, Flevari P, Sachanas S, Saetta AA, Sepsa A, Moschogiannis M, Kalpadakis C, Tsesmetzis N, Milionis V, Chatziandreou I, Thymara I, Panayiotidis P, Dimopoulou M, Plata E, Konstantopoulos K, Patsouris E, Piperi C, Korkolopoulou P.

Sci Rep. 2016 Feb 19;6:21252. doi: 10.1038/srep21252.

PMID: 26893254

 

Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.

Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, Kotsianidis I, Athina Viniou N.

Leuk Lymphoma. 2016 May;57(5):1182-8. doi: 10.3109/10428194.2015.1090573. Epub 2015 Dec 23.

PMID: 26373709

 

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Petrou E, Mavrogeni S, Karali V, Kolovou G, Kyrtsonis MC, Sfikakis PP, Panayiotidis P.

Rev Bras Hematol Hemoter. 2015 Jul-Aug;37(4):252-8. doi: 10.1016/j.bjhh.2015.03.014. Epub 2015 May 19.

PMID: 26190429

 

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I,Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P.

Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038/leu.2015.120. Epub 2015 May 14. No abstract available.

PMID: 25971363

 

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.

Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30.

PMID:26420061

 

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.

Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA.

Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. No abstract available.

PMID: 26359434

 

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.

Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA.

Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20. No abstract available.

PMID: 26294729

 

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy.

Sachanas S, Pangalis GA, Kalpadakis C, Levidou G, Yiakoumis X, Moschogiannis M, Kyrtsonis MC, Vassilakopoulos TP, Tsirkinidis P, Siakantaris M, Spiliadi C, Karagianni E, Korkolopoulou P, Rontogianni D, Papadaki H, Panayiotidis P, Angelopoulou M.

Leuk Lymphoma. 2015;56(11):3230-2. doi: 10.3109/10428194.2015.1034698. Epub 2015 May 12. No abstract available.

PMID: 25827212

 

New insights into malignant B-cell disorders.

Kyrtsonis MC, Shimizu K, Panayiotidis P, Pangalis GA.

Biomed Res Int. 2015;2015:128084. doi: 10.1155/2015/128084. Epub 2015 Jan 28. No abstract available.

PMID: 25695044

 

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

PMID: 25596264

 

Has the time come to reevaluate prognostic factors and to rebuild staging systems for multiple myeloma?

Kyrtsonis MC.

Eur J Haematol. 2015 Feb;94(2):95. doi: 10.1111/ejh.12429. No abstract available.

PMID: 25689635

 

Immunohistochemical expression of cell cycle proteins in multiple myeloma.

Pessach I, Papoudou-Bai A, Goussia A, Kamina S, Kyrtsonis MC, Bourantas KL, Kanavaros P.

Leuk Lymphoma. 2015;56(9):2720-3. doi: 10.3109/10428194.2015.1004171. Epub 2015 Feb 4. No abstract available.

PMID: 25573203